Literature DB >> 32502472

Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations.

Hsuan-Ping Chang1, Se Jin Kim1, Dhaval K Shah2.   

Abstract

Here we have reported whole-body disposition of wild-type IgG and FcRn non-binding IgG in mice, determined using Enzyme-Linked Immunosorbent Assay (ELISA). The disposition data generated using ELISA are compared with previously published biodistribution data generated using radiolabelled IgG. In addition, we introduce a novel concept of ABCIS values, which are defined as percentage ratios of tissue interstitial and plasma AUC values. These values can help in predicting tissue interstitial concentrations of monoclonal antibodies (mAbs) based on the plasma concentrations. Tissue interstitial concentrations derived from our study are also compared with previously reported values measured using microdialysis or centrifugation method. Lastly, the new set of biodistribution data generated using ELISA are used to refine the PBPK model for mAbs.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody biodistribution coefficient; Antibody interstitial concentration; Antibody pharmacokinetics; ELISA; Neonatal Fc receptor (FcRn); Tissue biodistribution

Mesh:

Substances:

Year:  2020        PMID: 32502472      PMCID: PMC7708505          DOI: 10.1016/j.xphs.2020.05.025

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  57 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

3.  Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Authors:  C Andrew Boswell; Daniela Bumbaca; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-31       Impact factor: 4.009

Review 4.  Microdialysis of large molecules.

Authors:  Geraldine F Clough
Journal:  AAPS J       Date:  2005-10-26       Impact factor: 4.009

Review 5.  Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer.

Authors:  Helge Wiig; Melody A Swartz
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

6.  Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.

Authors:  Sai Kiran Sharma; Andrew Chow; Sebastien Monette; Delphine Vivier; Jacob Pourat; Kimberly J Edwards; Thomas R Dilling; Dalya Abdel-Atti; Brian M Zeglis; John T Poirier; Jason S Lewis
Journal:  Cancer Res       Date:  2018-01-23       Impact factor: 12.701

7.  Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction.

Authors:  Fu Li; Michelle L Ulrich; Vincent Feng-Sheng Shih; Julia H Cochran; Joshua H Hunter; Lori Westendorf; Jason Neale; Dennis R Benjamin
Journal:  Mol Cancer Ther       Date:  2019-03-01       Impact factor: 6.261

8.  Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.

Authors:  Sukyung Woo; William J Jusko
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

9.  Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance.

Authors:  Cornelius Cilliers; Ian Nessler; Nikolas Christodolu; Greg M Thurber
Journal:  Mol Pharm       Date:  2017-03-31       Impact factor: 4.939

10.  Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption.

Authors:  Rafal Swiercz; Min Mo; Priyanka Khare; Zita Schneider; Raimund J Ober; Elizabeth Sally Ward
Journal:  Oncotarget       Date:  2017-01-10
View more
  10 in total

1.  Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.

Authors:  Hsueh-Yuan Chang; Shengjia Wu; Ekram Ahmed Chowdhury; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-01-29       Impact factor: 2.745

2.  PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.

Authors:  Shengjia Wu; Florie Le Prieult; Colin J Phipps; Mario Mezler; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-09-10       Impact factor: 2.410

Review 3.  Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation.

Authors:  Kenta Haraya; Haruka Tsutsui; Yasunori Komori; Tatsuhiko Tachibana
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-22

4.  Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.

Authors:  Hsuan-Ping Chang; Zhe Li; Dhaval K Shah
Journal:  Pharm Res       Date:  2022-01-19       Impact factor: 4.200

5.  Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.

Authors:  Paul R V Malik; Abdullah Hamadeh; Andrea N Edginton
Journal:  Pharm Res       Date:  2022-02-03       Impact factor: 4.200

6.  A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes.

Authors:  Eric Salgado; Yanguang Cao
Journal:  Antibodies (Basel)       Date:  2022-04-14

7.  Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies.

Authors:  Hanine Rafidi; Sharmila Rajan; Konnie Urban; Whitney Shatz-Binder; Keliana Hui; Gregory Z Ferl; Amrita V Kamath; C Andrew Boswell
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

8.  A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.

Authors:  Hsuan Ping Chang; Valentina Shakhnovich; Adam Frymoyer; Ryan Sol Funk; Mara L Becker; K T Park; Dhaval K Shah
Journal:  Br J Clin Pharmacol       Date:  2021-07-19       Impact factor: 3.716

Review 9.  Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.

Authors:  Yu Tang; Yanguang Cao
Journal:  Pharmaceutics       Date:  2021-03-21       Impact factor: 6.321

10.  Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid.

Authors:  Miro Julian Eigenmann; Tine Veronica Karlsen; Marek Wagner; Olav Tenstad; Tina Weinzierl; Tanja Fauti; Hans Peter Grimm; Trude Skogstrand; Christian Klein; Johannes Sam; Pablo Umana; Marina Bacac; Helge Wiig; Antje-Christine Walz
Journal:  Pharmaceutics       Date:  2021-12-07       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.